Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.74 +1.13 (+1.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,991,609
Open 65.92
Bid (Size) 66.50 (1)
Ask (Size) 66.66 (1)
Prev. Close 65.61
Today's Range 65.79 - 66.77
52wk Range 52.65 - 72.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
2 Steady Stocks to Buy and Hold Forever
Investing in these companies can help you sleep easy at night. 
Via The Motley Fool
P/E Ratio Insights for AstraZeneca
 
Via Benzinga

Performance

YTD
-3.74%
-3.74%
1 Month
-3.23%
-3.23%
3 Month
-1.08%
-1.08%
6 Month
+15.09%
+15.09%
1 Year
+5.14%
+5.14%

More News

Read More
A Look Into AstraZeneca's Debt
Via Benzinga
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
Via FinancialNewsMedia
Exposures Product Safety
AstraZeneca's Debt Overview
Via Benzinga
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
Via Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
Via Benzinga
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
From AstraZeneca
Via Business Wire
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
Via Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
3 No-Brainer Stocks to Buy With $400 Right Now
Via The Motley Fool
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
Via InvestorPlace
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
From AstraZeneca
Via Business Wire
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
From AstraZeneca
Via Business Wire
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
Via Benzinga
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
Via The Motley Fool
Why Compugen Shares Are Up Today
Via The Motley Fool
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Via Talk Markets
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
Via FinancialNewsMedia
Johnson & Johnson: Taking The Bull By The Horns?
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.